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DNA methylationThe DNA base 5-hydroxymethylcytosine (5hmC) is produced by enzymatic oxidation of 5-methylcytosine (5mC)
by 5mC oxidases (the Tet proteins). Since 5hmC is recognized poorly by DNA methyltransferases, DNA methyl-
ationmay be lost at 5hmC sites during DNA replication. In addition, 5hmC can be oxidized further by Tet proteins
and converted to 5-formylcytosine and 5-carboxylcytosine, two bases that can be removed fromDNA by base ex-
cision repair. The completed pathway represents a replication-independent DNA demethylation cycle. However,
the DNA base 5hmC is also known to be rather stable and occurs at substantial levels, for example in the brain,
suggesting that it represents an epigenetic mark by itself that may regulate chromatin structure and transcrip-
tion. Focusing on a few well-studied tissues and developmental stages, we discuss the opposing views of
5hmC as a transient intermediate in DNA demethylation and as a modiﬁed DNA base with an instructive role.
© 2014 Elsevier Inc. All rights reserved.1. Introduction
DNA cytosine methylation is a well-known epigenetic modiﬁcation
that occurs predominantly at CpG dinucleotide sequences in mammals.
The methylation state of CpG sites, being either unmethylated or meth-
ylated, has long been thought to be quite stable and is generally main-
tained during cell division by DNA methyltransferase enzymes that
transfer methyl groups from S-adenosylmethionine onto the cytosine
ring shortly after DNA replication [1,2]. However, during certain stages
of development and cell differentiation, methylation may be gained or
lost at speciﬁc genes or may change even genome-wide. Researchers
have long been fascinated by a poorly understood mechanism of DNA
demethylation that would remove methyl groups from DNA in an
enzymatic reaction that takes place in the absence of any DNA replica-
tion. Such a pathway has been known to occur for almost 30 years [3]
but its mechanism and enzymology have remained enigmatic and
controversial [4,5].
In 2009, a known product of oxidative damage to 5-methylcytosine
(5mC), 5-hydroxymethylcytosine (5hmC), was ‘rediscovered’ and
characterized as a relatively abundant enzymatically derived modiﬁ-
cation of 5mC in mammalian DNA [6,7]. The protein Ten-Eleven-
Translocation 1 (Tet1), previously implicated in chromosomal translo-
cations in leukemia [8,9], was shown to catalyze the oxidation of 5mC
to 5hmC in a reaction that depends on the cofactors Fe(II) and 2-
ketoglutarate [7]. Following the discovery of Tet1, the related pro-
teins Tet2 and Tet3 were also shown to have the same enzymaticactivity [10]. Tet proteins can oxidize 5mC to 5hmC and the oxidation
reaction can proceed to 5-formylcytosine (5fC) and 5-carboxylcytosine
(5caC) [11,12]. Furthermore, the pathway is continued by thymine-
DNA glycosylase (TDG), which recognizes and excises 5caC (and also
5fC) from DNA [11]. Base excision repair is then engaged for processing
of the resulting abasic site resulting eventually in appearance of unmod-
iﬁed cytosine and completion of a DNA methylation–demethylation
cycle (see Fig. 1) [11,13,14]. Although 5caC is chemically quite stable,
one other potential mechanism for removal of 5caC is enzymatic de-
carboxylation. However, no such decarboxylase enzyme has been
identiﬁed so far.
As outlined in Fig. 1A, 5hmC may be an intermediate in an active,
replication-independent DNA demethylation process. Moreover,
when present in DNA, 5hmC is a strong inhibitor of the DNA methyl-
transferase maintenance methylation reaction catalyzed by DNMT1
[15,16], leading to passive DNA demethylation over subsequent rep-
lication cycles (Fig. 1B). However, research over recent years also re-
vealed that this DNA base appears to play its own role in epigenetic
gene control. As will be discussed below, 5hmC is strongly associated
with genes and regulatory elements in the genome and is abundant
in brain, ES cells, primordial germ cells, and fertilized oocytes.
5hmC is depleted in many types of human cancer [17], a topic that
will not be discussed here in further detail but has been reviewed re-
cently [18,19] [see also review by Ficz and colleagues, this issue]. The
fact that 5hmC can be established by three different Tet enzymes,
Tet1, Tet2 and Tet3, which are differentially expressed during develop-
ment and tissue formation and target diverse genomic regions such as
gene body, promoters or enhancers, suggests that 5hmC may play a
multifaceted role in genome biology. In this review, wewill try to eluci-
date the dilemma as towhether 5hmC is just an intermediate product
Fig. 1. Active and passive DNA demethylation through 5-hydroxymethylcytosine (5hmC). A. Active DNA demethylation is catalyzed by TET-protein-mediated 5mC oxidation and base ex-
cision repair. B. Passive DNA demethylation is promoted by inhibition of DNMT1 at 5hmC-containing hemi-modiﬁed DNA strands.
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epigenetic code.
2. 5hmC in the brain
In 2009, the laboratory of Nathaniel Heintz described a surprisingly
high level of 5hmC, 0.6% and 0.2% of total nucleotides, in Purkinje and
granule cell neurons of the brain, respectively [6]. This work and a si-
multaneous report from the laboratory of Anjana Rao showing that
Tet1 is able to oxidize 5mC to 5hmC [7] marked the beginning of
the 5hmC era. The mammalian brain carries the highest level of
5hmC among all tissues analyzed so far reaching up to roughly 1%
of all cytosine bases in the human brain cortex [20,21]. This base is
most abundant in neurons; for example in cerebellar Purkinje cells
5hmC reaches almost 40% of 5mC levels [6]. In contrast to 5mC,
5hmC speciﬁcally occurs in the CpG dinucleotide sequence context
whereas 5mC is also commonly found at non-CpG sequences in the
brain [22]. Considering these numbers, one would be inclined to as-
sume that 5hmC must be a stable modiﬁcation. Otherwise, if 5hmC
represented a transient DNA modiﬁcation in the brain, then its turn-
over rate would need to be very slow.
5hmC is accumulating in human and mouse brains during the life
span, from neural progenitors through young neurons in the fetal
brain, and further during aging of the brain after birth [23–25]. In
mice, the accumulation of 5hmC in brain tissues continues with a
slower rate at 6 weeks of age. In contrast to 5hmC, the level of 5mC
seems to be decreasing during human brain aging [22]. It is important
to note that a simultaneous loss of 5mC and accumulation of 5hmC
were shown for the same genomic loci during primary synaptogenesis
and during neuronal differentiation [23,25]. In frontal cortex DNA,
genic regions of highly expressed neuron-speciﬁc genes gain 5hmC
between the fetus stage and 10 weeks of age [22]. However, detailedanalysis of 5hmC by TAB-sequencing at nucleotide resolution revealed
that the sum of methylated and hydroxymethylated cytosines remains
the same for the majority of DNA regions during neuronal differentia-
tion [23]. This fact suggests that 5hmC may partially replace 5mC in
the brain and indicates a particular stability of 5hmC in this tissue. The
concept of 5hmC stability in brain is clearly supported by the presence
of a very signiﬁcant level of 5hmC among all modiﬁed cytosine bases
and by 5hmC accumulation during aging [see also review by Sun and
colleagues, this issue].
If 5hmC is a stable epigenetic mark, then it is logical to propose
that 5hmC plays a regulatory function in the brain, where 5hmC
levels are the highest, and possibly also in other tissues. Such a role
may require the existence of speciﬁc 5hmC-binding proteins or
5hmC readers. Indeed, several putative 5hmC readers were identi-
ﬁed recently [26,27]. The best studied among them is methyl-CpG-
binding protein 2 (MeCP2), mutations of which are causatively asso-
ciated with the neurodevelopmental disorder Rett syndrome [28].
MeCP2 is able to bind 5hmC and 5mC with similar afﬁnities [26].
MeCP2 may activate transcription in brain since absence of MeCP2 in
knockout mice resulted predominantly in gene repression whereas
MeCP2 overexpression mostly caused activation of the same brain-
associated genes [29]. MeCP2 has been linked to increased chromatin
accessibility, which also positively correlates with 5hmC levels and
which is reduced in 5hmC-rich regions in MeCP2 KOmouse cerebellum
[26]. Therefore, a 5hmC-binding protein exists in brain and appears to
promote transcription and chromatin accessibility. The situation is far
from clear, however, since numerous prior studies had characterized
MeCP2 as a 5mC-binding transcriptional repressor [30]. It will be impor-
tant to determine whether the 5mC- or the 5hmC-binding properties of
MeCP2 are more important for preventing Rett syndrome.
Remarkably, according to different proﬁling methods, in brain,
the majority of 5hmC is accumulating in intragenic regions of
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positively correlates with gene transcript levels [20,23–25,31]. For in-
stance, gene activation is linked to accumulation of intragenic 5hmC
during neuronal differentiation in the developing mouse brain [23]. In
concordancewith theﬁnding that 5hmC is predominantly an active epi-
genetic mark in neuronal tissue, nuclear staining with anti-5hmC anti-
bodies indicates a clear euchromatin-speciﬁc pattern in contrast to the
5mC mark, which is concentrated in silent heterochromatin [23,26,32]
[see also review by Wen and Tang, this issue].
The possible transcription-promoting function of 5hmCwas demon-
strated in experiments usingmanipulation of TET proteins. All three TET
proteins have been associated with brain development and function.
During fetal development (E11.5–E15.5) Tet3 is the most abundant Tet
gene expressed, found in young neurons of the cortex where Tet1 is al-
most undetectable [23]. Knockdown of TET3 and TET2 by shRNA in vivo
negatively affects neuronal migration in the cortex and overexpression
promotes this process [23]. Conditional overexpression of Tet3 inmouse
mature olfactory sensory neurons revealed that 5hmC accumulation is
associated with gene activation in this cell type [33]. Moreover, it was
shown that learning processes are associated with TET3 activation and
5hmC redistribution in the cortex. When Tet3 was knocked down in
mice by shRNA, this event was associated with a decrease of 5hmC
level and learning failure [34]. Tet1 KOmice show phenotypes of abnor-
mal hippocampal long-term depression, affected memory and poor
learning [35,36] accompanied by downregulation of multiple neuronal
activity-regulated genes [36] and genes involved in adult neural pro-
genitor cell proliferation [35]. These data suggest that the mark, 5hmC,
and its “writers”, the TET proteins may play an important role in brain
function and development by regulating transcript levels of key
neuron-speciﬁc genes. Such ﬁndings, taken together with the facts
that 5hmC levels are so substantial in the brain and a speciﬁc reader,
MeCP2 exists in this tissue, would imply that this base is a stable DNA
mark and has a speciﬁc epigenetic regulatory function in neurons.
Differentially 5hmC-marked regions (DhMRs) exhibit dynamically
changing 5hmC levels during aging [22,25]. For instance, some genes
that will become activated later in development are marked by 5hmC
at their regulatory regions in fetal brain [22] suggesting a type of long-
term plasticity that depends on 5hmC. However, although 5hmC may
mark dormant genomic elements for future DNA hypomethylation
and gene activation, it would not be quite appropriate to refer to this
marking as a ‘transient’ or ‘intermediary’ state in the DNA demethyla-
tion pathway because of the long time span involved.
Similarly to 5mC [37] 5hmC levels also correlate with transcript
levels in gene bodies [20,23,24]. It is not known whether and how
5hmC enrichment along gene bodies promotes transcription. Based
on these recent ﬁndings, 5hmC may be more potent than 5mC in
opposing intragenic transcription initiation. Interestingly, a surprising
transcription-correlated 5hmC bias exists towards the sense DNA
strand and a 5mC bias towards the antisense strand is found within
gene bodies [38]. Highly expressed genes showed the strongest bias.
One possibility is that intragenic 5hmC, in particular when present on
the sense strand, opposes spurious intragenic or anti-sense transcrip-
tion. Different reports indicate that 5hmC is more strongly enriched in
exons and frequently is observed at exon/intron boundaries similar to
5mC [25,38–40]. Interestingly, DNA methylation positively affects
both MeCP2 binding and exon usage during splicing [41]. Taking into
account that MeCP2 binds with similar afﬁnity to 5hmC and 5mC, we
can hypothesize that the 5hmC level may regulate splicing through
MeCP2 in the brain where 5mC is substituted at least partially by
5hmC in gene bodies.
In contrast to intragenic 5hmC that marks active genes, 5hmC at
transcription start sites (TSS) often corresponds to an inactive/
repressed state of the linked gene [22,23,38,42,43]. In addition,
5hmC is often associated with adult-speciﬁc (poised) enhancers in
fetal brain and disappears upon enhancer activation. Therefore, 5hmC
may play a dual role in brain by marking inactive, poised enhancersand by promoting transcriptional activity when present within
gene bodies. Given that different TET proteins are associated with
speciﬁc genomic 5hmC patterning in ES cells — for instance, TET1 is
associated with 5hmC at promoters and TET2 is correlated with
genic 5hmC [44] — we can hypothesize that genic and enhancer-
associated 5hmC are also established by different members of the
TET family in brain.
However, despite of all these data suggesting a speciﬁc regulatory
role of 5hmC in the brain, the true stability of 5hmC in this tissue re-
mains unknown. There still is the possibility that 5hmC is an inter-
mediate product of DNA demethylation processes and that the
resulting unmethylated cytosines are quickly re-methylated and
then again oxidized, perhaps as part of memory or learning-related
processes, or perhaps even during each round of transcription. This
model would be consistent with the unusually high levels of DNMT3A
protein found in the nuclei of human and mouse brain [45–47] and
with theﬁnding that TDG is associatedwith DNMT3A [48]. If such a con-
tinuous cycling scenario were the case, going through every stage of
Fig. 1A at an even pace, then levels of 5caC and 5fC should also be
high and should be comparable to those of 5hmC in the brain. However,
5fC and 5caC occur at levels orders of magnitude lower than those of
5hmC in brain, as determined by very sensitive methods [12,49,50]. In
addition, single-stranded DNA breaks generated by TDG during the
DNA demethylation and repair process should be highly represented
in this tissue. Brain is indeed characterized by the presence of ssDNA
breaks, which were previously linked to ongoing oxidative DNA dam-
age in this tissue [51]. However, presence of ssDNA breaks negatively
interfereswith transcription [52]. On the other hand, a study of RNApo-
lymerase II activity revealed that presence of 5hmC in a DNA template
does not affect transcription, in contrast to 5fC and 5caC, which block
polymerase elongation [53]. In summary, there is currently nodirect ev-
idence that a continuously ongoing methylation–demethylation cycle
exists in the brain, or in any other tissue, although this possibility cannot
formally be excluded at this time.
One unresolved issue is why the enzymatic oxidation of 5mC
in vivo seems to stop in most instances at 5hmC, even though the
TET proteins are fully capable of producing 5caC in vitro [11,12].
There are at least two possible explanations. First, the activity of
TET proteins in vivomay be more strictly regulated disallowing further
oxidation of 5hmC except when true demethylation of the target
sequence is to be achieved. Second, 5fC and 5caC are also effectively
produced in vivo but are quickly removed by TDG or by other processes,
perhaps because the cellularmachinery views thesemodiﬁed bases as a
formofDNAdamage. In the latter situation, onewould expect the target
sequence to become fully demethylated almost instantaneously (which
is not the case, for example in brain) unless the sequences immediately
undergo re-methylation.
3. 5hmC in zygotes
Two rounds of genome-wide, potentially active DNA demethylation
events are executed during early development in mammals. Loss of
5mC occurs in primordial germ cells (PGCs) and in themale pronucleus
of fertilized oocytes [54]. Replication-dependent dilution of 5mC in pre-
implantation embryos was ﬁrst noticed by Rougier et al. [55]. Perhaps
the best-documented example of active DNAdemethylation is found al-
most immediately after fertilization when methylation seems to be re-
moved exclusively from the paternal genome [56]. This ‘loss’ of 5mC,
however, largely coincides with a conversion of 5mC into 5hmC
[57–59]. After fertilization, the paternal pronucleus is characterized by
a dramatic loss of 5mC staining beginning at the pronuclear stage 3
(PN3) and by appearance of the 5hmCmark. In contrast, the female pro-
nucleus remains enrichedwith 5mC [57–59]. TET3 is by far the predom-
inant TET activity present in oocytes and zygotes and its inactivation
inhibits 5mC conversion to 5hmC in the male pronucleus [57–59]. The
oocyte-speciﬁc protein PGC7 (DPP3A), binds to the H3K9me2 histone
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tion. This is, at least in part, responsible for the asymmetry betweenma-
ternal and paternal pronuclei [60,61]. How the 5hmC is eventually
processed in zygotes or early cleavage-stage embryos is still not entirely
clear. Using immunostaining experiments with anti-5hmC and anti-
5mC antibodies, it was found that 5hmC persists speciﬁcally on one
set of chromosomes throughout the ﬁrst mitotic division and is still
seen in 2- and 4-cell embryos [57] suggesting that 5hmC is s stable
DNAmodiﬁcation in zygotes. The gradual loss of 5hmC in preimplanta-
tion embryos appears to be largely replication-dependent [62] although
one needs to keep in mind that immunostaining is not quantitative. It
was shown that similar to 5hmC, 5fC and 5caC are also associated pre-
dominantly with the paternal pronucleus and become diluted during
replication [63]. These ﬁndings argue against a genome-wide, active
base removal process that produces completely demethylated cytosines
in zygotes. Intuitively, active DNA demethylation involving excision
repair of 5fC or 5caC by TDG, for example, should be an unlikely mech-
anism at this developmental stage, because the ﬁrst cell of the emerging
organism should not undergo genome-wide strand break repair on both
DNA strands, a process invariably associated with the risk of forming
lethal DNA double strand breaks.
Methylation levels in spermare higher than those in oocytes [64–66]
suggesting that there is a need for more rapid demethylation of the
paternal genome in order to achieve a balance of parental chromo-
some methylation and eventually reach a ground state of low meth-
ylation in the inner cell mass. Of note, reprogramming factors reside
predominantly in the male pronucleus [67]. A number of studies
have demonstrated the presence of unmethylated cytosines at dif-
ferent pronuclear stages of zygotes and in 2-cell embryos and often
the assumption has been made that such data reﬂect active DNA
demethylation [57,58,65,68,69]. However, one cannot exclude the
possibility that these unmethylated cytosines are the result of DNA
replication processes or that they reﬂect 5caC, which behaves identical
to cytosine in bisulﬁte sequencing reactions. On the other hand, if full
replication-independent conversion to cytosine can be convincingly
demonstrated for sperm-derived genomic loci, then 5hmC found in
the paternal pronucleus could be seen as a transient modiﬁcation at
those sequences leading to active demethylation. Despite recent data
that thematernal genome also may undergo active DNA demethylation
[65], given the prevailing evidence, it is likely that a combination of ac-
tive and passive demethylation processes occurs in early embryos and
that the paternal genomeuses an active in addition to a passive DNAde-
methylation pathway. Independent of the exactmechanism, 5hmCmay
be viewed as a transient DNA base that initiates DNA demethylation in
the sperm-derived genome of zygotes.
4. 5hmC in primordial germ cells
Following global zygotic DNA demethylation, a major wave of de
novo DNA methylation occurs from 3.5 to 6.5 dpc during embryo de-
velopment [64,70]. This highly methylated state is retained in the
soma but global erasure of 5mC takes place in the embryonic
germline as part of the reprogramming of soma into gametes [71].
Recent studies focused on whether this demethylation involves
5hmC. The progenitors of PGCs emerge from proximal epiblast cells
with characteristic expression of PRDM1 (BLIMP1) at 6.25 dpc and
PRDM14 at 6.5 dpc [72]. Immunostaining of embryo sections showed
that at 8.0 dpc DNA methylation is comparable in PGCs to neighbor-
ing somatic cells at the base of the allantois whereas migrating PGCs
at 8.0 dpc and 9.5 dpc have already substantially reduced 5mC stain-
ing, which appears even further reduced at 12.5 dpc in the gonads
[73]. Genome-wide mapping of DNA methylation using MeDIP-seq
and whole genome bisulﬁte sequencing (WGBS) methods conﬁrmed
that 5mC loss occurs in two steps. A fast, global demethylation before
9.5 dpc is followed by a slow, locus-speciﬁc demethylation in the late
migrating and gonadal PGCs [74,75]. This demethylation occurs inconnection with resetting the epigenome towards the germ lineage
[74–78] which includes the erasure of parental-allele-speciﬁc DNA
methylation marks at differentially methylated regions of imprinted
genes [79–83], and in turn, erasing imprinted gene expression [81,
84,85]. Global demethylation is complete by 13.5 dpc in both sexes
with a small set of escapee loci and IAP repeats that never get fully
demethylated [74–76,80].
Bisulﬁte sequencing showed that erasure of methylation at
imprinted differentially methylated regions (DMRs) occurs with var-
iable kinetics and is a late event as substantial DNA methylation can
be detected at DMRs at 11.5 dpc [80]. The demethylation at DMRs was
already initiated in migrating PGCs and reached completion in the go-
nadal PGCs [83,86]. DMR demethylation was never faster than the the-
oretical value calculated based on the preciselymeasured doubling time
of PGCs, which is 12.6 h between 9.5 dpc and 12.5 dpc, suggesting that
DNA demethylation in PGCs occurs largely by a passive dilution mech-
anism [86]. Support for this model comes from the fact that UHRF1
(Np95), a cofactor of themaintenancemethyltransferase DNMT1, is ex-
cluded from PGC nuclei and the de novo DNMTs are not expressed in
PGCs (DNMT3A) or excluded from the nucleus (DNMT3B) [73,75,86,
87]. However, demethylation at DMRs appeared in a mosaic pattern. It
was not disturbed at the H19 DMR when replication was blocked by
aphidicolin, but was reduced when the BER pathway was blocked by a
PARP inhibitor, 3-AB, suggesting an actively targeted process [83]. In ad-
dition, hairpin bisulﬁte sequencing results revealed that demethylation
occurs faster and slower than the theoretical passive and fully active de-
methylation values, respectively; therefore, it likely involves both
mechanisms [75].
Several lines of evidence suggest that DNA demethylation in PGCs
involves oxidation of 5mC to 5hmC. Tet1 and Tet2 but not Tet3 RNA
are detectable in PGCs [58,86–88]. Single cell analysis showed that
Tet1 was transcribed in PGCs at 9.25 dpc and in each Dppa3+ PGC at
11.5 dpc [89]. Tet2 was heterogeneously expressed at 9.25 and 10.25
but it was expressed in almost all Dpp3a+ PGC at 11.5 dpc. According
to immunostaining of PGCs, TET1 and TET2 proteins are highly
expressed and localized in the nucleus in PGCs at 9.5–11.5 dpc. Immu-
nostaining of PGCs showed that 5hmC staining transiently peaks in
PGCs between 9.5 and 10.5 dpc (between 10.5 and 11.5 dpc when
stained in embryo sections and exhibiting an increasingly dotted pat-
tern) and subsequently gradually diminishes, suggesting that 5hmC
represents an intermediate in PGC demethylation [88,90]. It was report-
ed, based on MeDIP-seq and hMeDIP-seq experiments that loss of 5mC
at exons paralleled 5hmC enrichment, suggesting that a 5mC to 5hmC
conversion took place at exons in PGCs [88]. Glu-PCR showed 5hmC en-
richment at the Dazl promoter, which is known to require DNAmethyl-
ation for its repression and is demethylated in PGCs. Meiosis was
impaired in Tet1−/− PGCs and corresponded to failed demethylation/
activation of a subset of meiosis-speciﬁc genes, Sycp1, Sycp3 and Mael.
Exons, introns, LTRs and IAPs were also affected [91]. These studies col-
lectively suggested a functional role for TET1 and perhaps TET2 in PGC
demethylation. Even though Tet1−/− PGCs displayed reduced 5hmC
staining, this was not accompanied by increased global 5mC levels as
detected by immunostaining or WGBS, suggesting that oxidation of
5mC by TET1 is not responsible for erasing the bulk of DNAmethylation
in PGCs [91]. The same result was reported for Tet1−/− Tet2−/− double
knockout (DKO) PGCs using immunohistochemistry of ovaries and tes-
tes at 13.5 dpc [88]. In agreement with this ﬁnding, mass spectrometry
showed that global DNA methylation was unchanged in DKO sperm.
The conversion of 5mC to 5hmC at imprinted DMRs was suggested
by the kinetics of these marks, measured by MeDIP and hMeDIP
[88]. Genetic studies give us clues about the possible roles of TET1
and TET2 in the erasure of genomic imprints. Offspring of Tet1−/−
[90] and Tet1−/−/Tet2−/− DKO mice [92] both exhibited variable
phenotypes that are consistent with incomplete imprint erasure.
There is controversy as to whether Tet1 KO alone results in failed PGC
demethylation and imprint erasure, and the reason for this is unclear
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cells exhibited variable phenotypes including early embryonic lethality
due to placental defects and neonatal lethality or fetal or postnatal
growth retardation. RNA-seq analysis and bisulﬁte sequencing experi-
ments revealed that numerous imprinted genes were misregulated in
the embryos and placentas. In addition, closely linked imprinted genes
(e.g. Peg10 and Sgce) were coordinately misregulated and the pattern
ofmisregulation often corresponded to hypermethylation ofmaternally
methylated imprinted DMRs (e.g. Peg10-Sgce DMR), consistent with
failed demethylation of thematernal allele inmale PGCs. Indeed, hyper-
methylation of maternal Peg10 DMRs was observed in Tet1−/− male
PGCs at 13.5 dpc. Reduced representation bisulﬁte sequencing (RRBS)
in 13.5 dpc Tet1−/− male germ cells and Tet1−/− sperm DNA showed
that the hypermethylation was not affecting the entire genome [90],
but rather a group of late-demethylating loci in the PGC genome, in-
cluding 7 out of 12 known maternal DMRs. The imprinting phenotypes
observed in paternally mutant Tet1+/− embryos can be traced back to
Tet1−/− sperm and even further to DNA defects of methylation erasure
in male Tet1−/− PGCs. Homozygous Tet1 mutation also had similar
effect in the erasure of imprinting in the female germline. Variable
phenotypes were observed in the offspring of Tet1−/− female mice,
including embryonic lethality and increased growth. Hypermethyla-
tion of paternally methylated Dlk1/Gtl2 (Meg3) and Rasgrf1 DMRs was
detected in the placentae of dead maternal mutant embryos consistent
with misregulation of the respective imprinted genes. Another group
reported that Tet1−/−/Tet2−/− DKO resulted in partially penetrant peri-
natal lethality [92]. SomeDKOmales that survivedwere fertile, but theirFig. 2.Model for imprinting defects in Tet-deﬁcient mice. Imprint erasure and establishment a
DMRs at imprinted genes are depicted as black and white circles, respectively. Paternally and
are gray. Imprint erasure is compromised in Tet1-deﬁcient mice as indicated by the asterisks.
the probability of inheriting the improperly remodeled allele is 50%. The level of demethylation
and/or lethality, depending on the role of the speciﬁc imprinted locus in development.Tet1+/−/Tet2+/− offspring exhibited partially penetrant lethality. Sur-
viving DKO females had smaller ovaries, fewer mature oocytes and
small litters, and only a small fraction of their Tet1-/+/Tet2−/−+ pups
survived to adulthood. It was reported, based on genome-wide MeDIP
assays, that the offspring of DKO male and female mice had increased
5mC levels across various imprinted loci. Bisulﬁte sequencing con-
ﬁrmed hypermethylation of maternal DMRs, Peg3 and Mest, in some
offspring of DKO male corresponding to silenced transcription of these
genes. Hypermethylation of paternal H19 DMR was also found in
some offspring of female DKO. However, DKO sperm DNA methylation
appeared normal at two maternally methylated DMRs. These authors
interpreted the ﬁndings as “the establishment of imprinting is compro-
mised in DKO gametes.” It is likely that erasure of methylation was de-
fective in DKO PGCs. These two studies collectively suggest that imprint
erasure in PGCs depends on TET-mediated oxidation. The variable phe-
notype is the results of incomplete erasure of DMRs in the mutant PGCs
with variable level of remaining DNA methylation per DMR per chro-
mosome and also from random distribution of the grandmaternally
and grandpaternally inherited chromosomes from the male or female
germlines, respectively. In Fig. 2 we depicted one pair of chromosomes
out of 20 with a maternally and paternally methylated imprinted DMR.
In addition to genetic studies, in vitromodel systems provided fur-
ther evidence for the role of TET1 and TET2 in PGC demethylation and
imprint erasure. Bisulﬁte sequencing showed that demethylation of
germline genes Dazl, Sycp3 and Mael, and repeat elements (IAP and
LINE-1) was impaired and imprinted DMRs demethylation did not
occur when Tet1 and Tet2 were knocked down in PGC-like culturedre shown for the male (left) and female (right) germlines. Methylated and unmethylated
maternally marked chromosomes are blue and red, respectively. Erased chromosomes
One chromosome is inherited from the germline via the sperm or oocyte. For each locus,
failure may be also variable for each locus. These micemay exhibit developmental failure
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reprogramming the genome of fused somatic cells by activating
pluripotency genes upon fusion. EGCs in addition have the capacity
to erase DNA methylation imprints at DMRs of imprinted genes
[93]. Bisulﬁte sequencing showed that upon fusing mouse B cells
with EGCs, DNA methylation decreased at the H19/Igf2, Dlk1/Gtl2
(paternal) and Peg3 (maternal) DMRs. A Mest promoter-beta galac-
tosidase transgene was demethylated and its transcription was
reactivated by the fusion. 5hmC accumulated at the H19/IGF2, PEG3
and SNURF DMRs in human DNA 48 h after fusion with EGCs.
ShRNA-mediated knockdown experiments suggested that Tet2 is re-
quired for the efﬁcient reprogramming capacity of EGCs, whereas
Tet1 was necessary to induce 5-methylcytosine oxidation-mediated
erasure of genomic imprints at DMRs [93]. Another study investigat-
ed the role of Tet1 and Tet2 in the in vitro PGC (iPGCs) formation from
ESCs. iPGCs recapitulate many aspects of in vivo PGC differentiation,
including the expression pattern for each of the Tet1 genes [89].
WGBS showed that iPGC differentiation and global DNA demethyla-
tion do not require Tet1 and Tet2, but a number of speciﬁc promoters
and gene bodies (including germline speciﬁc genes e.g. Tdrd5 and
Piwil4 and imprinted genes Snrpn and Peg3) exhibited DNA hyper-
methylation in Tet2−/− and Tet1 knockdown iPGCs. This again is con-
sistent with the notion that 5hmC is an intermediate in locus-speciﬁc
demethylation in PGCs that include imprinted genes.
What is unclear at present is to what extent the 5mC oxidation path-
way participates in the initial genome-wide wave of demethylation in
PGCs before 9.5 dpc. Because the late-demethylating imprinted loci
loose bisulﬁte-resistant moieties (5mC and 5hmC combined) with the
rate expected frompassive, replication-coupled demethylation, it is log-
ical to expect that the early phase of fast global demethylation should
involve some sort of active demethylationmechanism. Although genet-
ic knockouts suggest that TET-mediated oxidation is not required for
this global step, there still might be an important locus-speciﬁc role of
5mC oxidation to “kick-start” the demethylation process at certain
genomic sites. It will be important to map 5hmC in PGCs at early
demethylating loci. Interestingly, LINE1 elements and IAPs showed re-
duced 5hmC and elevated 5mC levels in Dppa3 null PGCs at 10.5 dpc,
suggesting that DPPA3 may perhaps target 5mC oxidation to these re-
peats in migrating PGCs [94]. This is, indeed, the opposite of what role
DPPA3 (PGC7) plays during zygotic demethylation [60] and it also oc-
curs in the virtual absence of H3K9me2 in PGCs [73]. In addition, a par-
tial role of DNA demethylation via deamination of 5mC by activation-
induced cytidine deaminase (AID, AICDA) was suggested based on bi-
sulﬁte sequencing of the PGC genome at 13.5 dpc [95]. Because Aid is
not expressed in the epiblast or in PGCs between 9.5 and 13.5 dpc [86,
87,89], AID might exert its activity between 7.5 and 8.5 dpc in the
early demethylation phase.
Immunostaining and mass spectrometry data suggest that a pas-
sive loss of 5hmC by replication-dependent dilution eliminates
5hmC after the Tet1-mediated oxidation step in PGCs [86,96]. This
data is in agreement with bisulﬁte sequencing data, because 5hmC
is another bisulﬁte-sequencing-positive DNA base [97,98]. TET pro-
teins can oxidize 5hmC further to 5fC and 5caC, but this process has
not been studied during PGC reprogramming [76,96]. All of the ex-
perimental evidence suggests that 5hmC represents an intermediate
(transient) stage during reprogramming of PGCs with one exception:
5hmC appears to be a stablemark at pericentric regions in oocytes up
to the germinal vesicle stage, consistent with lack of replication in
the female germline after 14.5 dpc [96].
Whole genome TAB-sequencing (WGTABS) experiments in normal
PGCs will reveal the precise dynamics of TET-mediated oxidation.
WGBS and WGTABS in Tet1−/−, Tet2−/− and DKO PGCs will unequivo-
cally determine the role of each TET protein in PGC demethylation. It
will be interesting to ﬁnd out what protects the speciﬁc loci from global
demethylation in the ﬁrst phase and how the active second phase is or-
chestrated. What mechanism is behind the considerable heterogeneitywith regard to demethylation of speciﬁc loci in the second phase? Tran-
scription factors and histone covalent modiﬁcations are likely involved.
Indeed, global reorganization of chromatin composition is an early
event in the epigenetic reprogramming of PGCs [73,99]. PRDM14 is an
important factor for PGC speciﬁcation and global reprogramming and
for their migration into the genital ridges [100]. Based on somewhat ar-
tiﬁcial but intriguing evidence— overexpressing of Prdm14 in ESCs — it
was suggested that PRDM14 might play a role in targeting TET1 and
TET2 to the pluripotency genes, germ cell genes and imprinted DMRs
in PGCs [101].
It is perhaps informative to compare the two major demethylation
events. Speciﬁc loci are protected from global TET3-mediated de-
methylation in the zygote's paternal pronucleus whereas speciﬁc
loci survive the ﬁrst wave of global demethylation in PGCs, and
these late demethylated regions are oxidized by TET1 and perhaps
TET2. What can be so different in the TET3 versus TET/TET2 enzymes
to act more globally or at speciﬁc sites? Further experiments need to
elucidate whether this depends on regulatory mechanisms affecting
TET protein function and/or their accessibility to DNA.
5. 5hmC in ES cells
ES cells contain 5hmC, which decreases upon differentiation [7].
Studies using knockdown strategies revealed that TET1, together
with TET2, plays a central role in maintaining the pluripotent state
since reduced TET activities caused ES cell differentiation, aberrant
DNA methylation of promoters and repression of genes important
for pluripotency including Nanog [10,32]. Inconsistent with this
data, Tet1/2 double knockout ES cells remained pluripotent, contrib-
uting to each germ layer in teratoma assays and contributed to chi-
meric embryos with the caveat that a skewed contribution to
extraembryonic lineage was observed in teratomas and develop-
mental defects occurred in chimeras, likely due to the group of devel-
opmental genes that became deregulated [92]. Further experiments
with Tet1/2/3 triple-knockout (TKO) ES cells revealed that Tet-TKO
embryoid bodies are characterized by aberrant methylation of pro-
moters and gene bodies and repression of key genes important for
development and cell differentiation thus compromising proper dif-
ferentiation of ES cells [102].
Remarkably, TET1 and TET2 show different localizations in the
genome of ES cells [44]. TET2 is present along with 5hmC along
gene bodies whereas TET1 is responsible for 5hmC deposition at pro-
moters and enhancers [44,103]. Proﬁling of TET1 in the ES cell ge-
nome revealed that TET1 binding is speciﬁcally enhanced at active
and bivalent promoters where TET1's presence is positively correlated
with the H3K4me3 mark [103,104]. 5hmC proﬁling in ES cells showed
some general similarities in 5hmC patterns with brain tissues. For
instance, in ES cells, 5hmC is accumulated at repressed promoters,
marks gene bodies of actively transcribed genes where it reﬂects
exon/intron structure and is associated with enhancers and p300
(Ep300) binding sites [40,43,103–105]. The speciﬁc genes marked by
5hmC along gene bodies, however, are different between ES cells, neu-
ronal cells, or other cell types reﬂecting which genes are expressed in a
particular type of tissue [106–108].
It is important to note that the TET1 binding pattern does not exactly
reﬂect 5hmC occupancy. TET1 mostly binds to active promoters where-
as, according to numerous proﬁling data, 5hmC is missing at active pro-
moters but is enriched at sequences immediately surrounding these
promoters. A similar situation is found at enhancers, which are associat-
ed with accumulation of 5hmC around p300 binding sites. This fact may
suggest that enhancers and active promoters undergo enhanced TET-
mediated surveillance for aberrantly introduced 5mC by extensive
5mC oxidation and possibly further oxidation and repair of 5hmC. This
suggestion was conﬁrmed by 5fC proﬁling in mouse ES cells with com-
promised TDG. Here TET1 binding sites were characterized by the
highest rate of 5hmC oxidation [109]. In the absence of TDG, 5fC and
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found at bivalent and repressed promoters, at p300 sites, and in gene
bodies of actively transcribed genes, particularly in exons [13,109].
Thus 5hmC conversion may occur continuously, which may indicate
that it is perhaps an unstable mark in ES cells at speciﬁc sites. One
should bear inmind, however, that in these Tdg knockout or knockdown
experiments, the levels of 5fC and 5caC were increased only ~2-fold to
~8-fold compared to the very low levels found in wildtype ES cells
[13,109]. If 5hmC were rapidly and continuously turned over to 5fC
and 5caC, their levels should be much higher than those reported in
ES cells lacking TDG.
On the other hand, TET activity and TDG are required for demethyl-
ation of keymicro RNA genes that are required for themesenchymal-to-
epithelial transition in mouse embryo ﬁbroblasts reprogrammed to-
wards pluripotency [14]. TDG knockdown leads to an increase in 5fC
and 5caC during neuronal and glial cell differentiation suggesting that
active DNA demethylation may occur at cell type-speciﬁc promoters
during lineage speciﬁcation [110]. In these settings, 5hmC, as well as
the higher oxidation products 5fC and 5caC, might function as transient
intermediates. Notwithstanding these perhaps special situations, how-
ever, the balance of the evidence is currently in favor of 5hmC being a
stable DNA modiﬁcation.
6. Is 5hmC a DNAmodiﬁcation that has mostly
methylation-inhibitory functions?
The question may be asked whether 5hmC is perhaps mostly a
negative mark that repels DNMT proteins and many methyl-CpG
binding proteins. Even before 5hmC has become known as an epige-
netic and enzymatically produced DNA modiﬁcation, earlier studies
by the laboratory of Lawrence Sowers investigated the effect of this
DNA modiﬁcation on a DNA methyltransferase and a methyl-CpG
recognizing protein domain [16,111]. Methylation of CpG sites by
DNMT1 is inhibited when 5hmC is present on one DNA strand [15,
16,112]. This blockage of maintenance DNA methylation will lead
to passive DNA demethylation and is thought to represent an impor-
tant biological function of 5hmC, being important for example during
PGC DNA demethylation and during demethylation of the paternal
genome after fertilization, as discussed above.
Earlier investigations showed that the methyl-binding domain of
MeCP2 was unable to bind to 5hmC [111], which is in apparent con-
trast to data by Mellén et al. [26]. Furthermore, it was shown that
several other proteins that contain an MBD domain, including
MBD1, MBD2, and MBD4 were all incapable of binding to 5hmC
[98]. One report suggested that MBD3, which displays poor binding
to 5mC, indeed interacts with 5hmC [113]. However, other studies
have come to a different conclusion and suggested poor binding of
MBD3 to 5hmC [15,114,115]. One other protein, initially identiﬁed
as a protein recognizing 5mC and promoting maintenance of DNA
methylation is UHRF1 [116]. UHRF1 and a related protein, UHRF2,
are capable of binding to 5hmC [27,117,118] and may help propa-
gate methylation patterns regionally by recruiting DNMT1. While
UHRF1 may have a better afﬁnity to 5mC than to 5hmC [119], the
binding of UHRF2 to 5hmC appears to be stronger than its binding to
5mC [27,118]. Their respective role in distinguishing between 5mC and
5hmC and their functions in vivo are not completely understood at this
time. Except perhaps for UHRF2, there is yet no well-characterized
protein that speciﬁcally recognizes the hydroxymethylated form of
cytosine. Interestingly, two studies based on mass spectrometric
analysis showed that the number of proteins binding to 5fC and
5caC is in fact much greater than the number of those binding to
5hmC even though these modiﬁcations are much less abundant
than 5hmC in tissues [27,120].
Viewing all the data combined, it seems not unreasonable to pro-
pose that the major biological effects of 5hmC are mostly negative
ones including the inhibition of DNA methyltransferases leading topassive DNA demethylation and the interference with methyl-CpG
recognizing inhibitory factors such as most of the MBD proteins.
Only MeCP2 and UHRF2 seem to have a reasonable or even preferen-
tial afﬁnity towards 5hmC when compared to 5mC. Steric hindrance
imposed by the hydroxymethyl groupsmay also negatively affect the
afﬁnity of other DNA binding proteins to their targets but this has not
yet been investigated in much detail.
7. Conclusions
So, in summary, how stable is 5hmC in cells? In one extreme view,
5hmC can be considered as very labile, similar to reversible chromatin
modiﬁcations, and much in contrast to 5mC, which has always been
thought to be exceptionally stable. The prevailing evidence based on
currently available data would suggest, however that 5hmC is indeed
rather stable in somatic tissues and serves speciﬁc biological functions
that may include speciﬁc readers such as UHRF2 and MeCP2. Yet, its
major functional role may in large part be based on blocking the inter-
action of 5mC-targeting proteins with DNA. During speciﬁc phases of
germ cell and early embryonic development, 5hmC can be considered
as a transient intermediate that promotes either passive, replication-
dependent or active DNA demethylation. There is accumulating evi-
dence that a TET-mediated active demethylation process also may
occur at certain genomic sequences during cell differentiation and
reprogramming. The available information suggests that there is a
regulatory step that determines at what developmental stage and at
what genomic loci oxidation of 5mC continues beyond the 5hmC base
to produce 5caC and eventually complete DNA demethylation by
converting 5caC to cytosine. In such gene-speciﬁc demethylation path-
ways, 5hmCwould indeed be a transient intermediate of the oxidation–
demethylation cycle but it would be difﬁcult to detect as such, similar to
5fC and 5caC, which turn over rapidly due to TDG-initiated base exci-
sion repair. Further studies are necessary to deﬁne the role of 5hmC as
both a stable and transient DNA modiﬁcation in various biological con-
texts including developmental stages, cell differentiation and disease
states.
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